These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
GH - Guardant Health, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$202.40
DETAILS
HIGH:
$225.00
LOW:
$180.00
MEDIAN:
$200.00
CONSENSUS:
$202.40
UPSIDE:
27.62%
Stock News
Guardant Health Shield Blood Test Demonstrates Leading Screening Adherence and CRC Deaths Averted Compared to Stool-Based Tests
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators presented new data showing
Guardant Health Shield Blood Test Demonstrates Leading Screening Adherence and CRC Deaths Averted Compared to Stool-Based Tests
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators presented new data showing the critical role of blood-based testing in increasing overall colorectal cancer (CRC) screening and follow-up colonoscopy adherence at the American College of Gastroenterology (ACG) 2026 Annual Meeting in Nashville, Tennessee. A modeling study looking at individuals 45 to 75 over a lifetime projected.
Reviewing The Pennant Group (NASDAQ:PNTG) and Guardant Health (NASDAQ:GH)
Guardant Health (NASDAQ: GH - Get Free Report) and The Pennant Group (NASDAQ: PNTG - Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, dividends and earnings. Earnings and Valuation This table compares Guardant
Guardant Health Announces Approval in Europe of Guardant360® CDx as Companion Diagnostic for AstraZeneca's ETCAMAH™ (camizestrant) in Advanced ER-positive Breast Cancer
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that Guardant360® CDx has received CE-marking under Europe's in Vitro Diagnostic Medical Devices Regulation as a companion diagnostic (CDx) to identify patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer who may benefit from treatment with ETCAMAH™ (camizestrant), AstraZeneca's next-generation oral selective estrogen.
Guardant Health to Report Third Quarter 2026 Financial Results on November 5, 2026
PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2026 after market close on Thursday, November 5, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the “Investors” section of the company website at: www.guardanthealth.com. The webcast wil.
Guardant Health (GH) Price Forecast: Breakout Opens Path Toward $250
Guardant Health reaches record highs as bullish patterns align across timeframes, opening potential upside toward $250 if buyers defend key breakout support.
Guardant Health COSMOS Study Published in Cancer Research Communications Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Melanoma
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced Cancer Research Communications, a journal of the American Association for Cancer Research, has published results from the COSMOS-MEL01 study (UMIN000042040). The study is the first published prospective, multicenter evaluation of the tissue-free, epigenomic Guardant Reveal™ blood test for molecular residual disease (MRD) detection and recurrence monitoring in patients wi.
Reviewing Guardant Health (NASDAQ:GH) & Privia Health Group (NASDAQ:PRVA)
Privia Health Group (NASDAQ: PRVA - Get Free Report) and Guardant Health (NASDAQ: GH - Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, institutional ownership, risk and valuation. Analyst Ratings This is a summary of
The Top HealthTech Questions Landing on Our Desks
Strong performance across the healthtech sector over the past two quarters has sparked renewed market interest in medical innovation. Given the volume of inquiries landing on our desks, we compiled this guide to answer a mix of the most frequent and most interesting questions we have received regarding our Healthcare Technology and Innovation Index (HTEC).
Reviewing Guardant Health (NASDAQ:GH) & CorVel (NASDAQ:CRVL)
CorVel (NASDAQ: CRVL - Get Free Report) and Guardant Health (NASDAQ: GH - Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, institutional ownership, earnings, risk and profitability. Risk and Volatility CorVel has a beta of 0.97,
AI-Fueled Precision Oncology Firm Guardant Health Is In Focus. Here's Why.
Earning a spot on the IBD Leaderboard and IBD 50, Guardant Health stress tests a breakout.
Guardant Health (NASDAQ:GH) versus InfuSystem (NYSE:INFU) Critical Review
Guardant Health (NASDAQ: GH - Get Free Report) and InfuSystem (NYSE: INFU - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, risk, institutional ownership, profitability, valuation and earnings. Earnings and Valuation This table compares Guardant Health and
Guardant Health (NASDAQ:GH) Director Sells $144,550.00 in Stock
Guardant Health, Inc. (NASDAQ: GH - Get Free Report) Director Alex Azar II sold 826 shares of Guardant Health stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $175.00, for a total value of $144,550.00. Following the completion of the sale, the director owned 825 shares of the
Guardant Health, Inc. (GH) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Guardant Health, Inc. (GH) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Guardant Health's Shield Blood Test Covered by EviCore by Evernorth for Colorectal Cancer Screening
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield™ blood test for colorectal cancer screening (CRC) will be covered in EviCore by Evernorth clinical guidelines effective January 1, 2027, per ACS guidelines. EviCore is a Cigna-owned company and the second largest specialty benefits manager in the country spanning more than 23 states. The latest policy update from Shield marks a rapid growth in commercial adopt.
Guardant Health and Collaborators to Present 20 Abstracts Highlighting Portfolio of Liquid Biopsy Tests for Early Detection and Ongoing Treatment Management at 2026 World Conference on Lung Cancer
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the company and its research collaborators will present 20 abstracts—including one mini oral presentation—showcasing advances in methylation-based tumor classification and liquid biopsy technology across lung cancer subtypes at the 2026 World Conference on Lung Cancer (WCLC). The conference is hosted by the International Association for the Study of Lung Cancer (IAS.
Business Insider Names Guardant Health One of America's Most Innovative Businesses
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it has been named to Business Insider's America's Most Innovative Businesses 2027 list, earning the highest rating available with a five-star recognition awarded to only other 12 biotechnology research companies in the category. The inaugural Business Insider list recognizes companies for their innovative performance over the preceding five years, positioning Guardant am.
Guardant Health Announces Landmark FDA Approval of Guardant360® CDx as Companion Diagnostic for AstraZeneca's ETCAMAH™ (camizestrant) in Advanced Breast Cancer
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360® CDx as a companion diagnostic (CDx) to identify patients with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer harboring tumors with ESR1 mutations before radiographic progression who may benefit from treatment with ETCAMAH™ (camizestrant), AstraZeneca's next-gener.
Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs
The biotech sector has a new catalyst beyond GLP-1 drugs. Moderna Inc (NASDAQ:MRNA) and Merck & Co Inc's (NYSE:MRK) positive Phase 3 results for a personalized mRNA cancer vaccine could revive investor interest in genomics, immunotherapy and precision medicine ETFs.
Price Targets
Guardant Health price target raised to $200 from $185 at Morgan Stanley
$200.00
(was $162.99)
Kallum Titchmarsh
·
Morgan Stanley
Guardant Health price target raised to $220 from $200 at Barclays
$220.00
(was $170.69)
Luke Sergott
·
Barclays
Guardant Health price target raised to $200 from $190 at Guggenheim
$200.00
(was $177.25)
Guggenheim
Bernstein SocGen Group Reiterates Outperform Rating on Guardant Health (GH)
$210.00
(was $161.25)
Eve Burstein
·
Bernstein
Guardant Health assumed with a Buy at UBS
$225.00
(was $160.98)
UBS
Guardant Health initiated with a Buy at Rothschild & Co Redburn
$203.00
(was $161.41)
Redburn Partners
Guardant Health price target raised to $185 from $175 at Morgan Stanley
$185.00
(was $160.36)
Morgan Stanley
Guardant Health price target raised to $195 from $170 at Stephens
$195.00
(was $158.83)
Stephens
Guardant Health price target raised to $193 from $135 at Piper Sandler
$193.00
(was $158.83)
Piper Sandler
Guardant Health price target raised to $200 from $185 at RBC Capital
$200.00
(was $161.87)
Dan Leonard
·
RBC Capital
Guardant Health (GH) PT Raised to $210 at TD Cowen
$210.00
(was $161.00)
RBC Capital
Guardant Health (GH) PT Raised to $180 at Stifel
$180.00
(was $152.35)
Daniel Arias
·
Stifel Nicolaus
Guardant Health price target raised to $210 from $185 at Goldman Sachs
$210.00
(was $152.35)
Goldman Sachs
Guardant Health (GH) PT Raised to $200 at Mizuho
$200.00
(was $152.35)
Anthony Petrone
·
Mizuho Securities
Guardant Health (GH) PT Raised to $195 at BTIG
$195.00
(was $152.35)
Mark Massaro
·
BTIG
Guardant Health price target raised to $200 from $150 at Barclays
$200.00
(was $152.35)
Barclays
Guardant Health (GH) PT Raised to $190 at GuggenheimMember Login
$190.00
(was $162.96)
Guggenheim
Guardant Health price target raised to $205 from $135 at Canaccord
$205.00
(was $158.40)
Kyle Mikson
·
Canaccord Genuity
Guardant Health price target raised to $175 from $130 at Morgan Stanley
$175.00
(was $156.17)
Morgan Stanley
Guardant Health price target raised to $200 from $160 at Evercore ISI
$200.00
(was $169.45)
Vijay Kumar
·
Evercore ISI